J Allergy Clin Immunol:哮喘和过敏性鼻炎患者中对TLR7/8激动剂的鼻粘膜干扰素和CCL13反应增加

2020-08-16 AlexYang MedSci原创

急性呼吸道病毒感染是呼吸道发病和死亡的主要原因,尤其是对于已有肺部疾病如哮喘的患者。Toll样受体(TLRs)在早期病毒检测和激活呼吸道黏膜先天性免疫中起着关键作用,但目前还没有可靠、方便的方法来检测

急性呼吸道病毒感染是呼吸道发病和死亡的主要原因,尤其是对于已有肺部疾病如哮喘的患者。Toll样受体(TLRs)在早期病毒检测和激活呼吸道黏膜先天性免疫中起着关键作用,但目前还没有可靠、方便的方法来检测呼吸道黏膜的先天性免疫反应。最近,有研究人员评估了健康和过敏志愿者中对先天免疫刺激的免疫响应情况,并进行了比较。

R848鼻挑战流程图

研究包括了健康非过敏参与者(n=12),过敏性鼻炎参与者(n=12)和哮喘过敏性鼻炎参与者(n=11),并分别进行TLR7/8激动剂瑞喹莫德(R848)或者生理盐水喷雾处理。研究发现,R848具有良好的耐受性并显著诱导鼻粘膜液体中的干扰素(IFN)-α2a、IFN-γ、促炎细胞因子(TNF-α、IL-2和IL-12p70)和化学因子(CXCL10、CCL2、CCL3、CCL4和CCL13),并不引起全身免疫激活。过敏性鼻炎参与者或者具有哮喘的过敏性鼻炎参与者与健康对照相比IFN-α2a增加,CCL3和CCL13响应增加;而那些具有哮喘的参与者的干扰素刺激基因DDX58、MX1和IFIT3诱导增加。

TLR7和8激动剂的鼻粘膜干扰素和CCL13反应增加

最后,研究人员指出,对R848的响应可以对鼻粘膜先天免疫响应进行简单的评估,具有过敏障碍的患者鼻粘膜干扰素和化学因子响应增加。他们的研究结果强调了过敏个体中鼻粘膜先天免疫响应的异常调控在病毒暴露结果中具有的作用。

原始出处:

Akhilesh Jha, Ryan S Thwaites, Tanushree Tunstall et al. Increased nasal mucosal interferon and CCL13 response to a TLR7/8 agonist in asthma and allergic rhinitis. J Allergy Clin Immunol. Jul 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1746631, encodeId=dbb71e46631e7, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Wed Sep 30 03:34:10 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047295, encodeId=1130204e29543, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 08 15:34:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994944, encodeId=73191994944d9, content=<a href='/topic/show?id=3a05103496c1' target=_blank style='color:#2F92EE;'>#鼻粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103496, encryptionId=3a05103496c1, topicName=鼻粘膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon Dec 14 00:34:10 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024644, encodeId=6e6c20246446e, content=<a href='/topic/show?id=7d7c1e53951' target=_blank style='color:#2F92EE;'>#TLR7#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17539, encryptionId=7d7c1e53951, topicName=TLR7)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Jul 04 15:34:10 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691074, encodeId=a79f16910e4e6, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Jun 06 13:34:10 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329405, encodeId=e5e31329405fe, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Aug 18 05:34:10 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627831, encodeId=092f162e83138, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Tue Aug 18 05:34:10 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809379, encodeId=9ac98093e989, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Aug 16 14:58:15 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
    2020-09-30 lilianxiang
  2. [GetPortalCommentsPageByObjectIdResponse(id=1746631, encodeId=dbb71e46631e7, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Wed Sep 30 03:34:10 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047295, encodeId=1130204e29543, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 08 15:34:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994944, encodeId=73191994944d9, content=<a href='/topic/show?id=3a05103496c1' target=_blank style='color:#2F92EE;'>#鼻粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103496, encryptionId=3a05103496c1, topicName=鼻粘膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon Dec 14 00:34:10 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024644, encodeId=6e6c20246446e, content=<a href='/topic/show?id=7d7c1e53951' target=_blank style='color:#2F92EE;'>#TLR7#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17539, encryptionId=7d7c1e53951, topicName=TLR7)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Jul 04 15:34:10 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691074, encodeId=a79f16910e4e6, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Jun 06 13:34:10 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329405, encodeId=e5e31329405fe, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Aug 18 05:34:10 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627831, encodeId=092f162e83138, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Tue Aug 18 05:34:10 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809379, encodeId=9ac98093e989, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Aug 16 14:58:15 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1746631, encodeId=dbb71e46631e7, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Wed Sep 30 03:34:10 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047295, encodeId=1130204e29543, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 08 15:34:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994944, encodeId=73191994944d9, content=<a href='/topic/show?id=3a05103496c1' target=_blank style='color:#2F92EE;'>#鼻粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103496, encryptionId=3a05103496c1, topicName=鼻粘膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon Dec 14 00:34:10 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024644, encodeId=6e6c20246446e, content=<a href='/topic/show?id=7d7c1e53951' target=_blank style='color:#2F92EE;'>#TLR7#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17539, encryptionId=7d7c1e53951, topicName=TLR7)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Jul 04 15:34:10 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691074, encodeId=a79f16910e4e6, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Jun 06 13:34:10 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329405, encodeId=e5e31329405fe, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Aug 18 05:34:10 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627831, encodeId=092f162e83138, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Tue Aug 18 05:34:10 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809379, encodeId=9ac98093e989, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Aug 16 14:58:15 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
    2020-12-14 jml2009
  4. [GetPortalCommentsPageByObjectIdResponse(id=1746631, encodeId=dbb71e46631e7, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Wed Sep 30 03:34:10 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047295, encodeId=1130204e29543, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 08 15:34:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994944, encodeId=73191994944d9, content=<a href='/topic/show?id=3a05103496c1' target=_blank style='color:#2F92EE;'>#鼻粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103496, encryptionId=3a05103496c1, topicName=鼻粘膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon Dec 14 00:34:10 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024644, encodeId=6e6c20246446e, content=<a href='/topic/show?id=7d7c1e53951' target=_blank style='color:#2F92EE;'>#TLR7#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17539, encryptionId=7d7c1e53951, topicName=TLR7)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Jul 04 15:34:10 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691074, encodeId=a79f16910e4e6, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Jun 06 13:34:10 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329405, encodeId=e5e31329405fe, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Aug 18 05:34:10 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627831, encodeId=092f162e83138, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Tue Aug 18 05:34:10 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809379, encodeId=9ac98093e989, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Aug 16 14:58:15 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
    2021-07-04 3631173
  5. [GetPortalCommentsPageByObjectIdResponse(id=1746631, encodeId=dbb71e46631e7, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Wed Sep 30 03:34:10 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047295, encodeId=1130204e29543, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 08 15:34:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994944, encodeId=73191994944d9, content=<a href='/topic/show?id=3a05103496c1' target=_blank style='color:#2F92EE;'>#鼻粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103496, encryptionId=3a05103496c1, topicName=鼻粘膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon Dec 14 00:34:10 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024644, encodeId=6e6c20246446e, content=<a href='/topic/show?id=7d7c1e53951' target=_blank style='color:#2F92EE;'>#TLR7#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17539, encryptionId=7d7c1e53951, topicName=TLR7)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Jul 04 15:34:10 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691074, encodeId=a79f16910e4e6, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Jun 06 13:34:10 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329405, encodeId=e5e31329405fe, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Aug 18 05:34:10 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627831, encodeId=092f162e83138, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Tue Aug 18 05:34:10 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809379, encodeId=9ac98093e989, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Aug 16 14:58:15 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
    2021-06-06 guoyibin
  6. [GetPortalCommentsPageByObjectIdResponse(id=1746631, encodeId=dbb71e46631e7, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Wed Sep 30 03:34:10 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047295, encodeId=1130204e29543, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 08 15:34:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994944, encodeId=73191994944d9, content=<a href='/topic/show?id=3a05103496c1' target=_blank style='color:#2F92EE;'>#鼻粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103496, encryptionId=3a05103496c1, topicName=鼻粘膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon Dec 14 00:34:10 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024644, encodeId=6e6c20246446e, content=<a href='/topic/show?id=7d7c1e53951' target=_blank style='color:#2F92EE;'>#TLR7#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17539, encryptionId=7d7c1e53951, topicName=TLR7)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Jul 04 15:34:10 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691074, encodeId=a79f16910e4e6, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Jun 06 13:34:10 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329405, encodeId=e5e31329405fe, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Aug 18 05:34:10 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627831, encodeId=092f162e83138, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Tue Aug 18 05:34:10 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809379, encodeId=9ac98093e989, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Aug 16 14:58:15 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
    2020-08-18 膀胱癌
  7. [GetPortalCommentsPageByObjectIdResponse(id=1746631, encodeId=dbb71e46631e7, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Wed Sep 30 03:34:10 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047295, encodeId=1130204e29543, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 08 15:34:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994944, encodeId=73191994944d9, content=<a href='/topic/show?id=3a05103496c1' target=_blank style='color:#2F92EE;'>#鼻粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103496, encryptionId=3a05103496c1, topicName=鼻粘膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon Dec 14 00:34:10 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024644, encodeId=6e6c20246446e, content=<a href='/topic/show?id=7d7c1e53951' target=_blank style='color:#2F92EE;'>#TLR7#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17539, encryptionId=7d7c1e53951, topicName=TLR7)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Jul 04 15:34:10 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691074, encodeId=a79f16910e4e6, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Jun 06 13:34:10 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329405, encodeId=e5e31329405fe, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Aug 18 05:34:10 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627831, encodeId=092f162e83138, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Tue Aug 18 05:34:10 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809379, encodeId=9ac98093e989, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Aug 16 14:58:15 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1746631, encodeId=dbb71e46631e7, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Wed Sep 30 03:34:10 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047295, encodeId=1130204e29543, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 08 15:34:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994944, encodeId=73191994944d9, content=<a href='/topic/show?id=3a05103496c1' target=_blank style='color:#2F92EE;'>#鼻粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103496, encryptionId=3a05103496c1, topicName=鼻粘膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon Dec 14 00:34:10 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024644, encodeId=6e6c20246446e, content=<a href='/topic/show?id=7d7c1e53951' target=_blank style='color:#2F92EE;'>#TLR7#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17539, encryptionId=7d7c1e53951, topicName=TLR7)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Jul 04 15:34:10 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691074, encodeId=a79f16910e4e6, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Jun 06 13:34:10 CST 2021, time=2021-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329405, encodeId=e5e31329405fe, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Aug 18 05:34:10 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627831, encodeId=092f162e83138, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Tue Aug 18 05:34:10 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809379, encodeId=9ac98093e989, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Aug 16 14:58:15 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
    2020-08-16 ms3000000449926787

    学习了!

    0

相关资讯

World Allergy Organ J:哮喘成年人中鼻高反应性的患病率和激发因子研究

鼻高反应性(NHR)是各种鼻炎亚型的一种常见特征,是鼻炎的一种新的表型。据报道,三分之二的鼻炎患者忽略了特应性反应。目前,关于哮喘患者的NHR患病率数据以及激发因子数据仍旧缺乏。

Sci Immun:科学家发现了T细胞亚群,可降低呼吸道过敏和哮喘的风险

导言:众所周知,遗传和环境是导致过敏和哮喘发生的两个主要因素。但过敏和哮喘是如何开始和产生的仍然是一个谜。最近《科学免疫学》杂志上发表了一篇文章,研究人员找出了一种以前未知的T细胞亚群,该亚群能够控制

Eur Respir J:哮喘患者骨质疏松和脆性骨折发病率

哮喘患者比普通人群更容易发生骨质疏松症或FF,尤其是年轻人和使用OCS和ICS的个体。

JAMA Intern Med :雷雨天前夕慢阻肺或哮喘发作增加!

近日,一项美国研究发现,雷雨天暴发前夕,哮喘和慢阻肺等呼吸道疾病急诊患者人数明显增加。研究者回顾医保数据,就1999~2012年间65岁以上有呼吸疾病者前往急诊就诊情况和当时天气情况进行了分析。

Eur Respir J:芬兰青年男性哮喘、变应性鼻炎和特应性湿疹的长期趋势

在芬兰,年轻男性的哮喘和过敏性疾病从1960年代中期开始增加很明显。增长速度在2000年代有所放缓,并可能在2020年代趋于平稳。

Int Arch Allergy Immunol:474名螨虫敏感患者中的Der P 23致敏分析

屋尘螨包括了一些过敏原组分,并能够引起常年过敏。最近,一种新的过敏原Der p 23在不同的欧洲国家具有相对较高的致敏比例。另外,Der p 23也被认为能够引起哮喘疾病。